Found: 10
Select item for more details and to access through your institution.
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2022, v. 23, n. 1, p. 52, doi. 10.1016/j.cllc.2021.08.012
- By:
- Publication type:
- Article
Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Defining a Space for NRG1 Fusion--Positive Tumors in Lung and GI Cancers.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 1, p. 28
- By:
- Publication type:
- Article
Amivantamab vs Mobocertinib in Exon 20 NSCLC.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 8, p. 340
- By:
- Publication type:
- Article
Preclinical Data Show Promise of Seribantumab in HER3-Positive Cell Lines.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 10, p. 685
- By:
- Publication type:
- Article
RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Post-Progression and Safety Outcomes With First-Line Amivantamab Plus Lazertinib Versus Osimertinib in EGFR-Mutated Advanced NSCLC: Implications for Best Management Practices.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2024, v. 15, n. 10, p. 314
- By:
- Publication type:
- Article
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article